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To the Editor:
We read with great interest the arti-
cle by Osarogiagbon et al.1 highlighting 
the role of accurate mediastinal staging 
of resected non–small-cell lung cancer 
(NSCLC). New surgical approaches have 
been proposed in the recent years in case 
of cT1a, N0, or N1 less than hilar NSCLC. 
These include sublobar resection, video-
assisted lobectomy, and robotic lobec-
tomy. Moreover, new lymphadenectomy 
approaches have been proposed and 
adopted in early-stage NSCLC, including 
lobe-specific lymphadenectomy in cT1a 
as proposed in Europe by the European 
Society of Thoracic Surgeons (ESTS) 
guidelines,2 and lymph node sampling 
according to the American College of 
Surgery Oncology Group Trial proposed 
by Darling et al.3 In early-stage NSCLC 
(clinically N0 with pathological nodule 
size ≤10 mm), systematic nodal dissec-
tion seems to be universally unnecessary 
as the risk of nodal involvement is very 
low. In this scenario, the patients selec-
tion for sublobar or lobar resection and 
the role of mediastinal sampling versus 
radical lymphadenectomy is actually cru-
cial because of the increasing proportion 
of lung cancer screening programs, and 
because of the new implications of the 
International Association for the Study of 
Lung Cancer/American Thoracic Society/
European Respiratory Society revision 
of the adenocarcinoma classification.4 
These could have profound implications 
for thoracic surgeons. Indeed, as reported 
by Van Schill et al.5 the new categories, 
adenocarcinoma in situ (AIS) and mini-
mally invasive adenocarcinoma (MIA) 
less than 3 cm, should have 100% 5-year 
disease-free survival after sublobar resec-
tion and mediastinal sampling. The defi-
nitions of AIS and MIA seem to overlap 
almost precisely with the kinds of small, 
less-aggressive tumors identified by the 
clinical evidence, like ground-glass opac-
ity (GGO). We completely agree with 
the Osarogiagbon et al.that most resec-
tions had suboptimal mediastinal lymph 
node examination up to 40%, according 
to Surveillance, Epidemiology and End 
Results and National Non-Communicable 
Diseases Program data sets, but maybe in 
a cT1 GGO-adenocarcinoma subset, the 
complete mediastinal lymph node exami-
nation (CMLE) may not be necessary. The 
analysis of the correlation among GGO, 
AIS/MIA histology, and limited resection 
without CMLE could strengthen the sur-
gical implications of the new adenocarci-
noma classification. In the near future, the 
role of the multidisciplinary team will be 
crucial in defining pre- and intraoperative 
early-stage AIS or MIA, and in tailoring 
and planning oncologically valid limited 
resections without CMLE.
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In Response:
Cafarotti et al.1 raise several ques-
tions about the optimal surgical lymph 
node staging procedure in patients with 
relatively low-risk non–small-cell lung 
cancer, especially adenocarcinoma in 
situ and minimally invasive adeno-
carcinoma. Their departure point was 
a report in this journal, of poor cor-
relation between surgical mediastinal 
lymph node examination claims and an 
audit of lymph nodes identified in the 
pathology report.2
The roles of minimally invasive 
lung resection and sublobar resection 
are not addressed in the reference pub-
lication.2 But neither the technique of 
resection (open, video-assisted, robotic-
assisted), nor the extent of resection 
(wedge, segmental, lobar, or more 
extensive) alter the need for an onco-
logically sound operation with nega-
tive margins and proper nodal staging. 
Until the results of the ongoing North 
American (Cancer and Leukemia 
Group B 140503 [ClinicalTrials.gov 
#00499330]) and Japanese (Japan 
Clinical Oncology Group 0802/West 
Japan Oncology Group 4607L) trials 
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of sublobar resection for small tumors 
with different percentages of ground-
glass opacity are available, caution must 
be exercised when recommending sub-
lobar resection even for ground-glass 
opacity lesions of 2 cm or less because 
local recurrence has been observed 
after a follow-up period of more than 5 
years.3
Because of its prognostic 
value and the limitations of clinical 
staging, proper pathologic staging of 
resected lung cancer is mandatory. The 
definition of proper has been debated. 
Accepted options range from (variously 
defined) systematic sampling to en-bloc 
systematic nodal dissection.4 American 
College of Surgeons Oncology Group 
Z0030 compared a thorough systematic 
node sampling (stations 2R, 4R, 7, and 
10R on the right; 5, 6, 7, and 10 L on 
the left) to a more extensive mediastinal 
lymph node dissection, and found no 
difference in survival.5 All patients 
in this study received a thorough 
systematic sampling procedure before 
randomization to cessation of further 
dissection, or completion of a more 
extensive dissection. This trial cannot 
be invoked in defence of any practice 
of less extensive dissection than 
noted above. The European Society 
for Thoracic Surgery accepts lobe-
specific nodal dissection for peripheral 
T1 squamous tumors, but requires 
examination of at least three mediastinal 
nodal stations, including station 7.4 
Attempts to limit mediastinal lymph 
node examination to less than selective 
dissection have adopted a sentinel 
lymph node examination strategy.6 
However, this has proven infeasible in 
clinical trials.7 There are no prospective 
studies of a strategy of no mediastinal 
lymph node examination, even in 
adenocarcinoma in situ and minimally 
invasive adenocarcinoma.
The reference report demon-
strated the unreliability of terminology 
thrown about to label the mediastinal 
lymph node examination procedure. 
Three observers (the operating surgeon, 
an auditing surgeon and the patholo-
gist in his final report) had poor con-
cordance in identifying the procedure 
performed. Most concordant cases were 
those in which no lymph node exami-
nation had been performed. Low lymph 
node counts suggested a severe problem 
in the quality of the examinations per-
formed overall. The authors suggested 
that the etiology of the problem was 
mainly in the operating room practice, 
but also entertained the possibility of 
problems in pathology examination 
practices because of greater concor-
dance between the operating and audit-
ing surgeons than between the surgeons 
and the pathologist.2 
The question of the optimal lymph 
node examination procedure for patients 
with ostensibly low risk of lymph node 
metastasis will increase in importance 
with adoption of computed tomography 
screening for lung cancer.8 However, 
there is currently no compelling 
evidence to support a strategy of 
ignoring the surgical lymph node 
examination. Unexpected lymph node 
metastasis can be detected in sufficient 
proportions of low-risk patients; hence 
this practice cannot be recommended, 
even in the era of positron emission 
tomography scans. In fact, two recent 
publications indicate that intraoperative 
nodal assessment should not be spared 
even in subcentimeter9 and in clinical 
T1a peripheral carcinomas.10
Molecular staging methods may 
someday enable us to identify patients 
at low risk for lymph node metastasis, 
in whom surgical lymph node 
examination would be superfluous. 
Some day, adjuvant therapy will 
become so effective that the presence 
of locoregional lymph node metastasis 
will lose its prognostic significance, 
as seems to have happened in breast 
cancer.11 We are not there yet. Although 
we will get there someday, the road to 
that destination is narrow, rocky, and 
uphill. It will take a tremendous amount 
of labor to identify truly independent 
molecular predictors, which must 
be prospectively validated in well-
characterized groups of patients in 
whom the best current prognostic tool, 
the pTNM staging system, has been 
correctly applied.12
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